Literature DB >> 2833765

Iodized oil in the portal vein after arterial embolization.

H Nakamura1, T Hashimoto, H Oi, S Sawada.   

Abstract

Transcatheter embolization with a relatively large amount (average, 17 mL) of iodized oil and doxorubicin hydrochloride with or without gelatin sponge particles was performed in 50 patients with hepatocellular carcinoma and in eight patients with liver metastases. After an intraarterial hepatic injection of an emulsion of iodized oil and doxorubicin hydrochloride, iodized oil was seen in the portal vein; the amount correlated with the amount that was injected, despite the lack of arterioportal shunting. Prominent portal vein appearances were seen in six of 21 cases (29%) given 10 mL or less of iodized oil, in 14 of 21 cases (67%) with 10-20 mL, and in 18 of 21 cases (86%) with more than 20 mL. Iodized oil may enter the portal vein through an arterioportal communication after pooling in the sinusoids.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2833765     DOI: 10.1148/radiology.167.2.2833765

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  24 in total

1.  Outcome of localized hepatocellular carcinoma treated with segmental arterioportal chemoembolization.

Authors:  H Nakamura; H Oi; S Hori; Y Takayasu; S Furui; S Sawada; T Kozuka
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial.

Authors:  Takahiro Yamasaki; Satoe Hamabe; Issei Saeki; Yohei Harima; Yuhki Yamaguchi; Koichi Uchida; Shuji Terai; Isao Sakaida
Journal:  J Gastroenterol       Date:  2010-08-25       Impact factor: 7.527

Review 3.  Advances in image-guided intratumoral drug delivery techniques.

Authors:  Luis Solorio; Ravi B Patel; Hanping Wu; Tianyi Krupka; Agata A Exner
Journal:  Ther Deliv       Date:  2010-08

4.  Bilio-enteric anastomosis as a risk factor for postembolic hepatic abscesses.

Authors:  K Okajima; S Kohno; M Tamaki; M Hosono; M Kawamoto; Y Nishiyama; M Sugano; T Miyaoka
Journal:  Cardiovasc Intervent Radiol       Date:  1989 May-Jun       Impact factor: 2.740

5.  Iodized oil accumulation in the hypovascular tumor portion of early-stage hepatocellular carcinoma after ultraselective transcatheter arterial chemoembolization.

Authors:  Shiro Miyayama; Osamu Matsui; Masashi Yamashiro; Yasuji Ryu; Harumi Takata; Taro Takeda; Hiroyuki Aburano; Noriaki Shigenari
Journal:  Hepatol Int       Date:  2007-11-14       Impact factor: 6.047

6.  Segmental transcatheter arterial embolization for primary hepatocellular carcinoma.

Authors:  Li Li; Pei-Hong Wu; Jin-Qing Li; Wei-Zhang Zhang; Hao-Gao Lin; Ya-Qi Zhang
Journal:  World J Gastroenterol       Date:  1998-12       Impact factor: 5.742

7.  Selection of therapeutic modalities for hepatocellular carcinoma in patients with multiple hepatic lesions.

Authors:  M Monden; M Sakon; M Gotoh; T Kanai; K Umeshita; K S Wang; M Sakurai; C Kuroda; J Okamura; T Mori
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Radiofrequency ablation in a porcine liver model: effects of transcatheter arterial embolization with iodized oil on ablation time, maximum output, and coagulation diameter as well as angiographic characteristics.

Authors:  Motoki Nakai; Morio Sato; Shinya Sahara; Nobuyuki Kawai; Hirohiko Tanihata; Masashi Kimura; Masaki Terada
Journal:  World J Gastroenterol       Date:  2007-05-28       Impact factor: 5.742

9.  Postoperative recurrence of hepatocellular carcinoma: results of transcatheter arterial chemoembolization.

Authors:  J H Park; J K Han; J W Chung; M C Han; S T Kim
Journal:  Cardiovasc Intervent Radiol       Date:  1993 Jan-Feb       Impact factor: 2.740

Review 10.  The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma.

Authors:  Sung Wook Shin
Journal:  Korean J Radiol       Date:  2009-08-25       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.